잠시만 기다려 주세요. 로딩중입니다.

Advanced Stage Hepatocellular Carcinoma Successfully Treated with Transarterial Radioembolization and Multi-tyrosine Kinase Inhibitor Therapy

대한간암학회지 2020년 20권 2호 p.160 ~ 166
고명지, 강원석, 신동현, 곽금연, 백용한, 최문석, 이준혁, 고광철, 백승운,
소속 상세정보
고명지 ( Goh Myung-Ji ) - Sungkyunkwan University School of Medicine Samsung Medical Center Department of Internal Medicine
강원석 ( Kang Won-Seok ) - Sungkyunkwan University School of Medicine Samsung Medical Center Department of Internal Medicine
신동현 ( Sinn Dong-Hyun ) - Sungkyunkwan University School of Medicine Samsung Medical Center Department of Internal Medicine
곽금연 ( Gwak Geum-Youn ) - Sungkyunkwan University School of Medicine Samsung Medical Center Department of Internal Medicine
백용한 ( Paik Yong-Han ) - Sungkyunkwan University School of Medicine Samsung Medical Center Department of Internal Medicine
최문석 ( Choi Moon-Seok ) - Sungkyunkwan University School of Medicine Samsung Medical Center Department of Internal Medicine
이준혁 ( Lee Joon-Hyeok ) - Sungkyunkwan University School of Medicine Samsung Medical Center Department of Internal Medicine
고광철 ( Koh Kwang-Cheol ) - Sungkyunkwan University School of Medicine Samsung Medical Center Department of Internal Medicine
백승운 ( Paik Seung-Woon ) - Sungkyunkwan University School of Medicine Samsung Medical Center Department of Internal Medicine

Abstract


Transarterial radioembolization (TARE) with yttrium-90 microspheres has become widely utilized in managing hepatocellular carcinoma (HCC). The utility of TARE is expanding with new insights through experiences from real-world practice and clinical trials, and recently published data suggest that TARE in combination with sorafenib may improve the overall survival in selected patients. Here, we report a case of advanced stage HCC that was successfully treated with TARE and sorafenib. The patient achieved complete response (CR) at 12 months after the initial treatment with TARE and sorafenib, followed by additional transarterial chemoembolization and proton beam therapy for local tumor recurrence at 19-month post-TARE. The patient was followed up every 3 months thereafter and still achieved CR both biochemically and radiologically for the following 12 months. A combination strategy of TARE and systemic therapy may be a useful alternative treatment option for selected patients with advanced stage HCC.

키워드

Hepatocellular carcinoma; Yttrium-90; Radioembolization; Sorafenib; Tyrosine kinase inhibitor

원문 및 링크아웃 정보

등재저널 정보